Bacitracin A

Bacitracin A forms a 1:1 complex with divalent metals, with the strongest binding affinity for Cu²⁺; Zn²⁺ is coordinated by Glu, His and the thiazoline ring. It binds to C₅₅-isopentenyl pyrophosphate (K = 1.1×10⁶ M^-1) in the presence of 1 mM Mg²⁺ at pH 7.5, and exhibits the highest affinity for inorganic pyrophosphate under 1 mM Zn²⁺ (K = 17800 M^-1)^[1].
Bacitracin A exhibits cytotoxicity against human renal tubular epithelial HK-2 cells, with an IC₅₀ of 4.22 μM after 48 h of in vitro incubation^[2].
Bacitracin A forms stable Co²⁺ and Zn²⁺ complexes: the cobalt complex binds undecaprenyl pyrophosphate (with a binding constant of 1.05×10⁶ M^-1), while the zinc complex binds phosphate and pyrophosphate derivatives^[3].
Bacitracin A (1×10^-7 M) completely inhibits the growth of Micrococcus lysodeikticus, which is consistent with its inhibitory effect on peptidoglycan biosynthesis^[1].
Bacitracin A binds to Micrococcus lysodeikticus cells with a K_m value of 3.7 × 10^-6 M, which is consistent with its interaction targeting C₅₅-isoprenyl pyrophosphate^[1].
Bacitracin A (20-200 μg/mL; 14 h) completely inhibits the growth of Escherichia coli SC 9251 when the outer membrane of the bacterium is disrupted by polymyxin-agarose^[1].
Bacitracin A (4-8 μM; 2 h) kills Gram-positive bacteria Staphylococcus aureus ATCC 29213 (MBC 4 μM), Streptococcus pneumoniae ATCC 49619 (MBC 8 μM), and Trueperella pyogenes ATCC 19411 (MBC 8 μM)^[2].
Bacitracin A (BA) (2-4 μM; 18-24 h) inhibits the growth of Gram-positive bacteria Staphylococcus aureus ATCC 29213 (MIC 2 μM), Streptococcus pneumoniae ATCC 49619 (MIC 4 μM), and Trueperella pyogenes ATCC 19411 (MIC 4 μM); it potently inhibits the growth of Micrococcus luteus ATCC 9341 (MIC 0.39 μg/mL), Staphylococcus aureus IFO 12732 (MIC 3.13 μg/mL), Bacillus cereus ATCC 11778 (MIC 6.25 μg/mL), and Micrococcus lysodeikticus (MIC 1×10^-7 M)^[2][3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.